Anti‐androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals

Anti‐androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals

The recently developed anti‐androgen enzalutamide also known as (MDV3100) has the advantage to prolong by 4.8 months the survival of castration resistant prostate cancer (CRPC) patients. However, the mechanisms behind the potential side effects involving the induction of the prostate cancer (PCa) ne...

Full description

Saved in:
Bibliographic Details
Main Authors: Qiang Dang, Lei Li, Hongjun Xie, Dalin He, Jiaqi Chen, Wenbing Song, Luke S. Chang, Hong-Chiang Chang, Shuyuan Yeh, Chawnshang Chang
Format: Article
Language:English
Published: Wiley 2015-08-01
Series:Molecular Oncology
Subjects:
Prostate cancer
Mast cells
IL8
NE differentiation
miRNA32
Online Access:https://doi.org/10.1016/j.molonc.2015.02.010
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1016/j.molonc.2015.02.010

Similar Items